The Emerging New Reality of Hypnosis Teletherapy: A Major New Mode of Delivery of Hypnotherapy and Clinical Hypnosis Training.

Remote hypnotherapy is a treatment that is increasingly being utilized internationally. Its adoption has been accelerated following the COVID-19 pandemic when infection control measures mandated its implementation. Remote hypnotherapy via video, rather than telephone therapy, appears to be more popular and effective, which appears to be acceptable to patients and - compared to face-to-face therapy - has the potential to improve access. In this state-of-the-art article, the authors therefore review the latest literature in this exciting field of remote teletherapy, discussing adoption of video hypnotherapy; its evidence, including efficacy compared to face-to-face therapy; patient satisfaction; advantages and disadvantages of teletherapy; as well as practical considerations and factors that should be considered when deciding on the mode of delivery. They also discuss training implications of the recent developments. Finally, they highlight areas for future research and development. Overall, it is likely that remote hypnotherapy via video platforms is here to stay long term and has potential to become the standard form of therapy worldwide. However, recent data suggest that there may still be a need for face-to-face therapy with patient choice being an important factor.

The symptom burden of Irritable Bowel Syndrome in tertiary care during the COVID-19 pandemic.

BACKGROUND: The COVID-19 pandemic caused unprecedented disruption to healthcare services worldwide with well-documented detrimental effects on mental health. Patients with refractory disorders of gut-brain interaction such as Irritable Bowel Syndrome (IBS) seen in tertiary care tend to exhibit higher levels of psychological comorbidity, but the impact of the pandemic on IBS symptom severity in tertiary care is unknown. METHODS: As part of routine clinical care, consecutive tertiary referrals with refractory IBS patients prospectively completed a series of baseline questionnaires including IBS symptom severity score (IBS-SSS), non-colonic symptom score, Hospital Anxiety and Depression (HAD), and Illness impact scores. The symptom severity questionnaire data were compared for consecutive patients seen in tertiary care 12 months before and after the onset of COVID-19 pandemic restrictions. KEY RESULTS: Of 190 consecutive tertiary referrals with IBS, those seen during the pandemic had greater IBS severity (IBS-SSS: 352 vs. 318, p = 0.03), more severe extra-intestinal symptoms (non-colonic score: 269 vs. 225, p = 0.03), sleep difficulties (p = 0.03), helplessness and loss of control (p = 0.02), but similar HAD-Anxiety (p = 0.96) and HAD-Depression (p = 0.84) scores. During the pandemic, unmarried patients (p = 0.03), and keyworkers (p = 0.0038) had greater IBS severity. CONCLUSIONS AND INFERENCES: This study has shown for the first time that patients seen in tertiary care with refractory IBS during the COVID-19 pandemic had a significantly higher symptom burden emphasizing the importance of gut-brain axis in IBS. Furthermore, lack of support and perceived loss of control appear to be contributory factors.